Form D · Pharmaceuticals
AEON Biopharma, Inc.
Irvine, CA · CIK 0001622667
Offering snapshot reported Aug 11, 2022 · SEC filing
- Reported sold
- $24.5M Offering amount: $25M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 8, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 11, 2022 | Initial | $24,500,000 | No comparison | 1 | SEC filing |
| Aug 11, 2022 | Initial | $30,000,000 | No comparison | 1 | SEC filing |
| May 13, 2021 | Amendment | $30,000,000 | No comparison | Not reported | SEC filing |
| Aug 31, 2020 | Initial | $25,000,000 | No comparison | 1 | SEC filing |
| Aug 10, 2016 | Initial | $5,500,000 | No comparison | 5 | SEC filing |
| Nov 20, 2015 | Initial | $80,060,118 | No comparison | 28 | SEC filing |
| Jan 22, 2015 | Initial | $27,000,015 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-455629
Pursuant to a Subord. Unsecured Convert. Prom. Note Purchase Agreement dated 12.8.21, as amended, the Company agreed to sell and issue, and a single accredited investor agreed to purchase, notes in an aggregate principal amount not to exceed $25,000,000.
The convertible promissory notes may be paid in cash or converted into an indeterminate number of shares of Common Stock.
Source: Form D, filed Aug 11, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Scott Akamine | Executive |
| Juliet Tammenoms Bakker | Director |
| Simone Blank | Director |
| Chris Carr | Executive |
| Christopher Cox | Director |
| Jost Fischer | Director |
| Marc Forth | Executive |
| Jeevan Gore | Executive |
| Robert Grant | Director |
| Bosun Hau | Director |
| Robert Hayman | Director |
| Hans S. Keirstead | Director |
| Craig Kussman | Executive |
| Richard Lindstrom | Director |
| William Link | Director, Executive |
| James Xiaodong Liu | Director |
| Vikram Malik | Director |
| Patrick Maxwell | Director |
| Darren O'brien | Director |
| Chad Oh | Executive |
| Robert Rhatigan | Executive |
| Bill Richardson | Director |
| Richard Taketa | Director |
| Valerie Taupin | Director |
| Alex Wilson | Executive |
| Dennis Wolf | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
5 Park Plaza Suite 1750
Irvine, CA, 92614
Irvine, CA, 92614